This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameTrebananib
Accession NumberDB12056
TypeBiotech
GroupsInvestigational
Description

Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon Cancer, among others.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs Amg 386
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIX8Y5U6NC7E
CAS number894356-79-7
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Amg 386.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Amg 386.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amg 386.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Amg 386.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Amg 386.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Amg 386.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Amg 386.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amg 386.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Amg 386.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Amg 386.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Amg 386.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Amg 386.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Solid Neoplasm / Lung Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Uterine Corpus Sarcoma / Renal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IV Renal Cell Cancer / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAdvanced Solid Tumors / Impaired Renal Function / Kidney Diseases1
1CompletedTreatmentCancer, Ovarian / Cancers / Carcinoma NOS / Fallopian Tube Cancer / Gynecological Malignancies / Metastases / Oncology / Tumors / Tumors, Solid1
1CompletedTreatmentCentral Nervous System Neoplasms / Solid Neoplasms1
1CompletedTreatmentNeoplasms, Advanced Solid1
1CompletedTreatmentTumors1
1RecruitingTreatmentAdvanced Solid Tumors1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Oligodendroglioma / Recurrent Adult Brain Neoplasm1
2Active Not RecruitingTreatmentAdvanced Renal Cell Carcinoma1
2Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentProstate Cancer / Prostate Neoplasms / Prostatic Neoplams / Prostatic Neoplasms1
2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentAdult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentAdvanced Hepatocellular Carcinoma / Inoperable Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentCancers / Carcinoma NOS / Colorectal Cancers / Gastrointestinal Cancers / Malignant Neoplasm of Colon / Metastases / Metastatic Cancers / Metastatic Colorectal Cancers / Oncology / Rectal Carcinoma1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Endometrioid Stromal Sarcoma / Recurrent Uterine Corpus Carcinoma1
2CompletedTreatmentGastrointestinal Cancers1
2CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
2WithdrawnTreatmentTransitional Cell Carcinoma1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
3TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
Properties
StateNot Available
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on October 20, 2016 15:16 / Updated on June 28, 2017 10:03